Cytokinetics, Incorporated (CYTK)

Market Cap	5.83B
Revenue (ttm)	85.74M
Net Income (ttm)	-606.31M
Shares Out	119.66M
EPS (ttm)	-5.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,943,623
Open	49.70
Previous Close	49.76
Day's Range	48.11 - 51.71
52-Week Range	29.31 - 59.39
Beta	0.62
Analysts	Buy
Price Target	75.57 (+55.05%)
Earnings Date	Nov 5, 2025

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 498
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Analyst Summary

According to 15 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price target is $75.57, which is an increase of 55.05% from the latest price.

Price Target

$75.57

(55.05% upside)

Analyst Consensus: Buy